Lambert-Eaton myasthenic syndrome: Difference between revisions

No edit summary
 
(14 intermediate revisions by 6 users not shown)
Line 1: Line 1:
==Background==
==Background==
*Autoantibodies against Ca channels of axon nerve terminals responsible for ACh release
*Disease of the neuromuscular junction leading to primary presentation of weakness
*Epidemiology
*Caused by auto-antibodies against the voltage-gated calcium channels at the NMJ
**Predominantly a disease a/w older men w/ history of cigarette smoking and lung cancer
 
***50% of pts have concurrent small-cell lung cancer  
===Epidemiology===
**Syndrome can precede detection of malignancy by several years
*Predominantly a disease associated with older men with history of cigarette smoking and lung cancer
**50% of patients have concurrent small-cell lung cancer  
*Syndrome can precede detection of malignancy by several years
*Paraneoplastic syndrome in 60-70% of cases


==Clinical Features==
==Clinical Features==
*Fluctuating symmetric weakness and fatigue, esp of proximal leg muscles
*Often presents with alteration in gait or difficulty rising from a chair
*Fluctuating symmetric [[weakness]] and fatigue, especially of proximal leg muscles
*Improvement in strength with sustained or repeated exercise (in contrast to MG)
*Improvement in strength with sustained or repeated exercise (in contrast to MG)
**Lambert sign: handshake strength increases over several seconds
**Lambert sign: handshake strength increases over several seconds
*Myalgias
*[[Myalgia]]s
*Muscle stiffness (especially in hip and shoulders)
*Muscle stiffness (especially in hip and shoulders)
*Paresthesias
*[[Paresthesia]]s
*Metallic taste
*Metallic taste
*Autonomic symptoms (dry mouth, impotence)
*Eye movements are unaffected
*Eye movements are unaffected
*Sensory examination normal
*Sensory examination normal
*Autonomic dysfunction (dry mouth, erectile dysfunction)
*Compared with myasthenia gravis, LEMS begins with lower extremities weakness and rarely begins with extraocular muscle weakness
*[[Respiratory failure]] can occur in late stages of the disease
*Paraneoplastic and autoimmune form of LEMS have similar signs and symptoms


==Differential Diagnosis==
==Differential Diagnosis==
{{Weakness DDX}}
{{Weakness DDX}}


==Diagnosis==
==Evaluation==
 
==Treatment==
*Supportive (progression to respiratory or bulbar failure is rare)
*Acetylcholinesterase inhibitors (e.g. pyridostigmine) can improve symptoms
 
==Disposition==
*Admission required when infectious complications occur or when severe disability requires inpatient immunotherapy
 
==See Also==
*[[Myasthenia Gravis]]
 
==References==
 
[[Category:Neuro]]
 
==Background==
*Disease of the neuromuscular junction leading to primary presentation of weakness
*Caused by auto-antibodies against the voltage-gated calcium channels at the NMJ
 
==Clinical Features==
*Often presents with alteration in gait or difficulty rising from a chair
*Symmetrical muscle weakness and fatiguability often beginning in lower extremities
*Autonomic dysfunction (dry mouth, erectile dysfunction)
*Compared with myastenia gravis, ELS begins with lower extremities weakness and rarely begins with extraocular muscle weakness
*Respiratory failure can occur in late stages of the disease
*Paraneoplastic and autoimmune form of LEMS have similar signs and symptoms
 
==Differential Diagnosis==
*Myasthenia Gravis
*Myositis
*Dermatomyositis
*Amyotrophic Lateral Sclerosis
*Limb-Girdle Muscle Dystrophy
*Inclusion Body Myositis
 
==Diagnosis==
*Diagnosis is generally a clinical diagnosis
*Diagnosis is generally a clinical diagnosis
*Confirmation testing for VGCC antibodies
*Confirmation testing for VGCC antibodies
Line 63: Line 34:


==Management==
==Management==
*Supportive (progression to respiratory or bulbar failure is rare)
*[[Acetylcholinesterase inhibitors]] (e.g. [[pyridostigmine]]) can improve symptoms
*Guanidine
*Guanidine
*Aminopyridines
*Aminopyridines: 2-10 mg/day
*Acetylcholinesterase inhibitors
*[[IVIG]]
*IVIG
*[[Glucocorticoids]]
*Glucocorticoids
*[[Plasma exchange]]
*Plasma exchange


==Disposition==
==Disposition==
*Admission required when infectious complications occur or when severe disability requires inpatient immunotherapy
*Referral to rheumatology
*Referral to rheumatology
*Any patients with risk factors for small cell lung cancer will need to be referred for evaluation of underlying malignancy
*Any patients with risk factors for small cell lung cancer will need to be referred for evaluation of underlying malignancy


==See Also==
==See Also==
 
*[[Myasthenia Gravis]]
==External Links==


==References==
==References==
<UpToDate>
<references/>
[[Category:Neurology]]

Latest revision as of 22:14, 5 January 2020

Background

  • Disease of the neuromuscular junction leading to primary presentation of weakness
  • Caused by auto-antibodies against the voltage-gated calcium channels at the NMJ

Epidemiology

  • Predominantly a disease associated with older men with history of cigarette smoking and lung cancer
    • 50% of patients have concurrent small-cell lung cancer
  • Syndrome can precede detection of malignancy by several years
  • Paraneoplastic syndrome in 60-70% of cases

Clinical Features

  • Often presents with alteration in gait or difficulty rising from a chair
  • Fluctuating symmetric weakness and fatigue, especially of proximal leg muscles
  • Improvement in strength with sustained or repeated exercise (in contrast to MG)
    • Lambert sign: handshake strength increases over several seconds
  • Myalgias
  • Muscle stiffness (especially in hip and shoulders)
  • Paresthesias
  • Metallic taste
  • Eye movements are unaffected
  • Sensory examination normal
  • Autonomic dysfunction (dry mouth, erectile dysfunction)
  • Compared with myasthenia gravis, LEMS begins with lower extremities weakness and rarely begins with extraocular muscle weakness
  • Respiratory failure can occur in late stages of the disease
  • Paraneoplastic and autoimmune form of LEMS have similar signs and symptoms

Differential Diagnosis

Weakness

Evaluation

  • Diagnosis is generally a clinical diagnosis
  • Confirmation testing for VGCC antibodies
  • Neurophysiologic testing

Management

Disposition

  • Admission required when infectious complications occur or when severe disability requires inpatient immunotherapy
  • Referral to rheumatology
  • Any patients with risk factors for small cell lung cancer will need to be referred for evaluation of underlying malignancy

See Also

References